CN104940427B - Blood sugar reducing composition containing wolfberry fruits and application and preparation method thereof - Google Patents
Blood sugar reducing composition containing wolfberry fruits and application and preparation method thereof Download PDFInfo
- Publication number
- CN104940427B CN104940427B CN201510429197.5A CN201510429197A CN104940427B CN 104940427 B CN104940427 B CN 104940427B CN 201510429197 A CN201510429197 A CN 201510429197A CN 104940427 B CN104940427 B CN 104940427B
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- raw materials
- medlar
- blood sugar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention provides a hypoglycemic food, health-care product or pharmaceutical composition containing medlar, which comprises the following raw materials in parts by weight: 1-10 parts of wolfberry fruit, 10-20 parts of malus hupehensis leaves and 1-5 parts of raspberry. The research of the invention finds that the combination of the medlar and the malus hupehensis leaves has the synergistic effect, and the hypoglycemic activity is improved and is better than the single use of the medlar and the malus hupehensis leaves. Meanwhile, the invention further discovers that after the medlar and the malus hupehensis leaves are combined in a specific ratio (5: 15), the hypoglycemic effect is better than that of other ratios (1: 10 and 10: 10) in the experiment. Based on the research, the invention provides a novel hypoglycemic composition, and provides a new choice for clinical medication and health care treatment.
Description
Technical Field
The invention belongs to the field of health care products, and particularly relates to a hypoglycemic food, health care product or pharmaceutical composition containing wolfberry.
Technical Field
According to statistics, the number of people suffering from diabetes in China currently reaches 9240 ten thousands, which is the first to live all over the world (Yang W, equivalent. N Engl J Med, 2010, 362 (12): 1090-1101). The treatment cost of diabetes in China is up to 1734 billion yuan each year, and the direct medical expenses caused by diabetes already account for 13 percent of the total medical expenses in China (Alcorn T, et al. Lancet, 2012, 379 (9833): 2227-2228). Therefore, diabetes not only seriously harms people's health, but also brings a heavy economic burden to the nation. Therefore, the prevention and treatment of diabetes are not easy.
The medlar is a mature fruit of Lycium chinense Mill or Lycium barbarum L of Solanaceae, can nourish liver and kidney, replenish essence and nourish blood, improve eyesight and remove nebula, moisten lung and relieve cough, and is mainly used for treating diseases such as kidney deficiency, impotence and spermatorrhea, long-term infertility, premature senility, premature graying hair, blood deficiency and sallow complexion, less postpartum milk, dim and unclear eyes, internal heat and thirst, fatigue and heat and bone steaming, consumptive disease and cough, dry cough and less phlegm and the like.
Folium Mali Hupehensis is young leaf or old leaf of Malus Hupehensis (Pamp.) Rehd of Rosaceae, and the young leaf can be used for removing food retention, regulating stomach, invigorating spleen, and preventing principal food retention; dyspepsia; dysentery; malnutrition with accumulation. Modern pharmacological research finds that the malus hupehensis leaves have a certain blood sugar reducing effect.
Raspberry (Rubus idaeus L.) also known as Rubus corchorifolius, Rubus idaeus, etc., belongs to Rubus genus of Rosaceae family. The raspberries are mainly distributed in temperate zone and cold zone of northern hemisphere, and the fruits are multi-pulp small polymerized fruits which are sweet and slightly sour in taste. The raspberry contains various active ingredients such as polysaccharide, organic acid, flavone, anthocyanin, polyphenol, vitamin, mineral elements, volatile oil, tannin and the like, has extremely high nutritive value and medical care function, and is known as 'golden fruit'.
At present, no report about the combined use of the medlar, the leaf of Malus hupehensis and the raspberry is found.
Disclosure of Invention
The invention aims to provide a composition for reducing blood sugar. The invention also provides a preparation method and application of the composition.
Specifically, the invention provides a food, a health product or a pharmaceutical composition for reducing blood sugar, which comprises the following raw materials in parts by weight:
1-10 parts of wolfberry fruit, 10-20 parts of malus hupehensis leaves and 1-5 parts of raspberry.
Further, the raw materials of the material comprise the following components in parts by weight:
5-10 parts of wolfberry fruit, 15-20 parts of malus hupehensis leaves and 3-5 parts of raspberry.
Furthermore, the raw materials of the material comprise the following components in parts by weight:
5 parts of wolfberry fruit, 15 parts of malus hupehensis leaf and 5 parts of raspberry.
The weight ratio of the raw materials is calculated by dry products, and if the raw materials are fresh products or water-containing products, the raw materials can be converted according to the water content.
Wherein the composition is in a form for oral administration.
Wherein the raspberry (Rubus idaeus L.) is fruit of Rubus genus plant of Rosaceae family.
Wherein the raspberry is selected from red raspberry or black raspberry.
Further, the oral administration dosage form is selected from granules, powder, tea, pills, tablets or capsules.
The invention also provides a preparation method of the food, the health care product or the pharmaceutical composition, which comprises the following operation steps:
(1) taking raw materials according to the proportion;
(2) mixing the raw materials uniformly, adding water for extraction, adding appropriate amount of adjuvants or auxiliary components into the extractive solution, and making into food, health product or pharmaceutical composition.
The invention also provides another preparation method of the food, the health-care product or the pharmaceutical composition, which comprises the following operation steps:
(1) taking raw materials according to the proportion;
(2) mixing the raw materials uniformly, extracting with ethanol and water, adding appropriate amount of adjuvants or auxiliary components into the extract, and making into food, health product or pharmaceutical composition.
The invention also provides the application of the composition in preparing medicines, health products or foods for reducing blood sugar.
Further, the medicine, health-care product or food is a medicine, health-care product or food for preventing or treating type I and type II diabetes mellitus or/and diabetic complications.
The research of the invention finds that:
(1) after the medlar and the malus hupehensis leaves are combined for use, the synergistic effect is exerted, and the hypoglycemic activity is improved and is superior to that of the medlar and the malus hupehensis leaves which are used independently. Meanwhile, the invention further discovers that after the medlar and the malus hupehensis leaves are combined in a specific ratio (5: 15), the hypoglycemic effect is better than that of other ratios (1: 10 and 10: 10) in the experiment.
(2) The combination of the medlar, the leaf of the malus hupehensis and the raspberry can also play a good role in reducing blood sugar, and the pharmacodynamic activity is stronger than that of the compatibility of every two of the medlar and the leaf of the malus hupehensis.
Based on the research, the invention provides a novel hypoglycemic composition, and provides a new choice for clinical medication and health care treatment.
Detailed Description
Example 1: preparation of the compositions of the invention
Mixing fructus Lycii, folium Mali Hupehensis and Rubi fructus at a weight ratio of 5: 15: 5 (calculated on dry basis), decocting in water for 30min for 2 times, and mixing extractive solutions to obtain decoction.
Example 2: preparation of the compositions of the invention
Mixing fructus Lycii, folium Mali Hupehensis, and Rubi fructus at a weight ratio of 1: 10: 1 (calculated on dry basis), sequentially extracting with 70% v/v ethanol and water under reflux for 30min for 2 times, recovering ethanol from ethanol extractive solution, mixing with water extractive solution, concentrating, adding appropriate amount of dextrin and microcrystalline cellulose, and making into granule.
Example 3: preparation of the compositions of the invention
Taking fructus Lycii, folium Mali Hupehensis and Rubi fructus at a weight ratio of 10: 20: 3 (calculated on dry basis), drying, pulverizing, mixing, adding appropriate amount of microcrystalline cellulose, mixing, and making into powder.
Example 4: preparation of the compositions of the invention
Taking fructus Lycii, folium Mali Hupehensis and Rubi fructus at a weight ratio of 5: 15: 3 (calculated on dry basis), drying, mixing, and making into teabag.
Example 5 hypoglycemic Effect test of the composition of the present invention
1) Experimental drugs:
group A: mixing fructus Lycii and folium Mali Hupehensis at a weight ratio of 5: 15 (calculated on dry basis), decocting in water for 2 times (30 min each time), mixing extractive solutions, concentrating to 200ml, and collecting extract A.
Group B: mixing fructus Lycii and folium Mali Hupehensis at a weight ratio of 1: 10 (calculated on dry basis), decocting in water for 2 times (30 min each time), mixing extractive solutions, concentrating to 200ml, and collecting extract B.
Group C: mixing fructus Lycii and folium Mali Hupehensis at a weight ratio of 10: 10 (calculated on dry basis), decocting in water for 2 times (30 min each time), mixing extractive solutions, concentrating to 200ml, and collecting extract C.
Group D: decocting fructus Lycii 200g in water for 2 times, each for 30min, mixing extractive solutions, and concentrating to 200ml to obtain extract D.
Group E: taking 200g of Hubei Chinese flowering crabapple leaves, adding water, decocting and extracting for 2 times, each time for 30min, combining extracting solutions, and concentrating to 200ml to obtain an extract E for later use.
And F group: decocting raspberry 200g in water for 2 times (30 min each time), mixing extractive solutions, and concentrating to 200ml to obtain extract F.
Group G: mixing fructus Lycii, folium Mali Hupehensis and Rubi fructus at a weight ratio of 5: 15: 5 (calculated on dry basis), decocting in water for 30min for 2 times, mixing extractive solutions, concentrating to 200ml, and collecting extract G.
The dosage is calculated according to the weight of the rat, and the low dosage, the medium dosage and the high dosage of the gavage are respectively 1ml/kg, 2ml/kg and 4ml/kg (measured by extractum).
2) Animals: four-week-old Kunming rat, male, normal grade, 135g, provided by Gansu Chinese medicine college. Experiments were carried out after one week of rearing in cages placed in the laboratory (10 per cage, temperature 22. + -. 1 ℃ C., humidity 42%. + -. 2%). Grouping: the drug composition is a blank group (no model is made by citric acid buffer solution for intravenous injection, and the stomach is filled with ultrapure water), a model group (STZ model for tail vein injection, and the stomach is filled with ultrapure water), a positive drug group (STZ model for tail vein injection, and the stomach is filled with glibenclamide 20 mg/kg), low-dose groups A1, B1, C1, D1, E1, F1, and G1 (STZ model for tail vein injection, and the stomach is filled with 1ml/kg) of the drug composition of the invention), medium-dose groups A2, B2, and C2 (STZ model for tail vein injection, and the stomach is filled with 2ml/kg) of the drug composition of the invention, and high-dose groups A3, B3, and C3 (STZ model for tail vein injection, and the stomach is filled with 4ml/kg of the drug composition of the invention) respectively. The molding method comprises the following steps: fasting is carried out for 16h in advance, then, the blood glucose is measured after 60mg/kg of tail vein injection of STZ (prepared by citric acid buffer solution) and 72 hours after injection, and whether the model is successful or not is tested.
3) The experimental process comprises the following steps: healthy SD rats were randomly divided into a blank group, a model group, a positive drug group and low, medium and high dose groups. Distilled water was administered to the blank group and the model group by gavage every day; the positive medicine group is administrated with glibenclamide for 1 time per day; the test drug groups were administered 1 time per day by gavage, each group was administered 28 days continuously, and blood glucose was measured 12 hours after the last administration and recorded.
4) Results of the pharmaceutical composition of the present invention for reducing blood glucose in diabetic rats
TABLE 1 Effect of the pharmaceutical compositions of the present invention on STZ-induced blood glucose in rats (Mean SD)
Note: comparison with Normal groupap＜0.05，aap is less than 0.01; comparison with model groupbp＜0.05，bbp is less than 0.01; compared with the same dosage group of A groupcp＜0.05，ccp＜0.01
As can be seen from Table 1:
(1) the pharmaceutical composition has obvious effect of reducing blood sugar of STZ-induced diabetic rats under low dose, and has significant difference (p is less than 0.05 or 0.01) with a model group.
(2) According to the invention, A, B, C groups respectively have 3 different proportions, and the comparison of the three shows that group A is better than group B, C (p is less than 0.05 compared with group A with the same dosage), therefore, the proportion of the medlar and the malus hupehensis leaves in the invention is preferably the proportion of group A.
(3) The wolfberry fruit or the malus hupehensis leaves with the same concentration are independently used, the trend of reducing blood sugar is realized at low dose, but the blood sugar reducing effect is not obvious, the obvious difference (p is more than 0.05) of the blood sugar reducing activity of the wolfberry fruit or the malus hupehensis leaves compared with a model group is obvious, and the blood sugar reducing activity of the wolfberry fruit or the malus hupehensis leaves is obviously not better than the combination of the wolfberry fruit and the malus hupehensis leaves, so that the synergistic effect is exerted after the wolfberry fruit and the malus hupehensis leaves are combined for use.
In addition, the raspberry is added into the group G of the invention, and the blood sugar reducing effect of the composition at the same concentration is better than that of a composition only containing the medlar and the malus hupehensis leaves (the dosage effect is equivalent to that of a pairwise compatible group), which also shows that the raspberry, the medlar and the malus hupehensis leaves can play a synergistic effect when being compatible for use, and the blood sugar reducing activity is improved.
Claims (7)
1. The blood sugar reducing pharmaceutical composition containing the barbary wolfberry fruit is characterized by comprising the following raw materials in parts by weight: 5 parts of wolfberry fruit, 15 parts of malus hupehensis leaf and 5 parts of raspberry.
2. The pharmaceutical composition of claim 1, wherein the composition is in an orally administrable form.
3. The pharmaceutical composition of claim 2, wherein the orally administrable formulation is selected from the group consisting of granules, powders, teas, pills, tablets and capsules.
4. A process for preparing a pharmaceutical composition according to claim 1, wherein: the method comprises the following operation steps:
(1) taking raw materials according to the proportion;
(2) mixing the raw materials uniformly, adding water for extraction, and adding appropriate amount of adjuvants or auxiliary components into the extractive solution to obtain the pharmaceutical composition.
5. A process for preparing a pharmaceutical composition according to claim 1, wherein: the method comprises the following operation steps:
(1) taking raw materials according to the proportion;
(2) mixing the raw materials uniformly, extracting with alcohol and water, adding appropriate amount of adjuvants or auxiliary components into the extract, and making into pharmaceutical composition.
6. Use of a composition according to any one of claims 1 to 3 for the manufacture of a medicament for lowering blood glucose.
7. Use according to claim 6, characterized in that: the medicine is used for treating type I and type II diabetes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510429197.5A CN104940427B (en) | 2015-07-20 | 2015-07-20 | Blood sugar reducing composition containing wolfberry fruits and application and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510429197.5A CN104940427B (en) | 2015-07-20 | 2015-07-20 | Blood sugar reducing composition containing wolfberry fruits and application and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104940427A CN104940427A (en) | 2015-09-30 |
| CN104940427B true CN104940427B (en) | 2020-03-31 |
Family
ID=54155853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510429197.5A Active CN104940427B (en) | 2015-07-20 | 2015-07-20 | Blood sugar reducing composition containing wolfberry fruits and application and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104940427B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104758309A (en) * | 2015-04-04 | 2015-07-08 | 中国科学院西北高原生物研究所 | Application of strawberry polysaccharide in reduction of blood sugar |
-
2015
- 2015-07-20 CN CN201510429197.5A patent/CN104940427B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104758309A (en) * | 2015-04-04 | 2015-07-08 | 中国科学院西北高原生物研究所 | Application of strawberry polysaccharide in reduction of blood sugar |
Non-Patent Citations (2)
| Title |
|---|
| 枸杞降血糖作用的药效学研究;谭淑敏;《南方医科大学学报》;20081231;第28卷;第2103-2014页，尤其是第2104页4讨论 * |
| 湖北海棠叶治疗2型糖尿病疗效观察;公丕军等;《实用糖尿病杂志》;20111231;第7卷(第4期);第34-35页，尤其是第35页3讨论项下 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104940427A (en) | 2015-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2436388B1 (en) | Composition for increasing the bioavailability of saponin | |
| KR102262306B1 (en) | Composition for relieving premenstrual syndrome and menstrual pain | |
| US10111451B2 (en) | Food, beverage or pharmaceutical composition containing fermented eastern prickly pear and a preparation method therefor | |
| KR101874462B1 (en) | Composition for preventing, ameliorating or treating atopic dermatitis comprising Schisandra chinensis leaf extract as effective component | |
| CN104383315A (en) | Chinese herbal medicinal composition for protecting liver and sobering and drink containing Chinese herbal medicinal composition | |
| CN104958588B (en) | A kind of composition using miracle fruit leaf as primary raw material and its application as drug or health care product | |
| CN110613134B (en) | Health food with blood sugar reducing function and preparation method thereof | |
| KR101794006B1 (en) | Anti inflammatory comprising plant extract | |
| CN108813501A (en) | With the relieving cough and reducing sputum health honey paste relievingd asthma and adjust function of human body of clearing heat and moistening lung | |
| CN106581115B (en) | Composition containing yuankanin and ginseng and application thereof | |
| CN104940428B (en) | Hypoglycemic composition containing wolfberry fruits and application thereof | |
| KR101732483B1 (en) | Composition for prevention, improvement or treatment of peripheral neuropathy comprising Forsythiae Fructus extract as effective component | |
| CN114209758A (en) | Traditional Chinese medicine compound composition capable of maintaining blood sugar health level and preparation method and application thereof | |
| CN105031033B (en) | Blood sugar reducing pharmaceutical composition containing boxthorn leaves and preparation method and application thereof | |
| CN104940427B (en) | Blood sugar reducing composition containing wolfberry fruits and application and preparation method thereof | |
| KR102343245B1 (en) | Composition for preventing, ameliorating or treating atopic dermatitis comprising Chrysanthemum indicum L. oil extract as effective component | |
| KR102282839B1 (en) | Composition for relieving or improving hangover | |
| CN108813500B (en) | Health-preserving honey paste with effects of tonifying middle-jiao and Qi, nourishing blood and soothing nerves and regulating human body functions | |
| KR20140080289A (en) | Composition for preventing or treating of oxidative brain injury and brain function disorder | |
| CN100534461C (en) | Pharmaceutical composition for treating diabetes and impaired glucose tolerance and preparation method thereof | |
| KR101479096B1 (en) | Health functional food comprising extracts of herbal mixture for preventing or improving edema of delivered or pregnant woman | |
| CN108379500B (en) | Wheat seedling traditional Chinese medicine composition for nourishing liver, dispelling effects of alcohol, sobering up and preventing halitosis and preparation method thereof | |
| KR101735294B1 (en) | Composition for preventing or treating of oxidative brain injury and brain function disorder | |
| KR102494072B1 (en) | Composition for improving or preventing depression comprising herbal extracts and method for preparing thereof | |
| CN114601891B (en) | Composition with anti-ulcerative colitis effect and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |